Welcome to our dedicated page for TRINITY BIOTECH PLC SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc announced successful clinical study results for an enhanced version of its EpiCapture™ prostate cancer test and outlined commercialization plans, while also obtaining a limited waiver under its Credit Agreement. The upgraded urine-based test now uses a machine learning algorithm that integrates DNA biomarkers with patient features such as ethnicity to improve individualized risk prediction for aggressive prostate cancer.
In an independently conducted study of approximately 750 patient samples, the next-generation EpiCapture™ achieved a clinical accuracy (AUC) of 85%, a level described as strong and clinically useful in oncology diagnostics. Trinity Biotech plans to launch EpiCapture™ in the U.S. as a proprietary Laboratory Developed Test through its New York reference laboratory, marking its first entry into precision oncology diagnostics. The company also disclosed that, under the limited waiver for covenant 8.15 with Perceptive Credit Holdings III, interest accruing in March 2026 will be capitalized and added to the principal balance of its debt.
Trinity Biotech plc filed a Form 6-K highlighting two growth initiatives in diabetes care. Senior executives are attending the ATTD 2026 conference in Barcelona to advance collaborations and commercialization plans for the next‑generation CGM+ continuous glucose monitoring platform, which is being prepared for a pivotal clinical trial in 2026.
The company has also begun commercial rollout in Brazil of its upgraded Premier Hb9210 HbA1c column system after local regulatory approval. The Premier Hb9210 platform is described as the only HbA1c system worldwide with IFCC “Gold” classification for 2026, and Trinity Biotech has strengthened its Brazilian commercial leadership with the appointment of Bruna Gigliotti.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.
Trinity Biotech plc updates its prospectus to register for resale up to 705,659,320 Ordinary Shares, represented by up to 35,282,966 ADSs. The supplement incorporates Form 6-K reports filed March 10, 2026, describing technical breakthroughs for its next‑generation CGM+ continuous glucose monitoring platform and a trading and business update.
The company reports substantial multi‑day clinical-data improvements in glucose measurement accuracy (material reduction in MARD), anticipates initiating a pivotal clinical trial in 2026, and states the CGM+ design targets modularity, multimodal sensing, and AI-native analytics. Separately, Trinity obtained a limited waiver and a covenant deferral under its credit agreement through July 1, 2026.
Trinity Biotech plc reports major technical progress on its next-generation, calibration‑free CGM+ continuous glucose monitoring platform, supported by more than 650 days of clinical testing data. The updated sensor and electronics architecture materially improved glucose measurement accuracy across multi‑day wear, indicating the system can meet modern CGM accuracy standards.
The company also developed a needle‑free insertion process and a modular device design aimed at lowering costs and improving sustainability versus current market‑leading CGMs. CGM+ uses multimodal sensing and AI‑native analytics to generate personalized metabolic health insights, and Trinity Biotech anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets afterward.
Trinity Biotech plc filed a Form 6-K sharing a trading and business update and disclosing amendments to its credit covenants. The company obtained a limited waiver of covenant 8.16 and a deferral of a scheduled change to covenant 8.15 under its Credit Agreement with Perceptive Credit Holdings III, both effective through July 1, 2026.
Operationally, Trinity Biotech is advancing a Comprehensive Transformation Plan aimed at improving long-term profitability. It received local regulatory approval in February 2026 to outsource and offshore production of its Uni-Gold HIV rapid test, enabling the final transition of manufacturing. Strong demand for Uni-Gold HIV and growing traction for TrinScreen are expected to increase the share of rapid HIV products in 2026 revenue, but order patterns and the outsourcing transition are anticipated to increase quarter‑on‑quarter revenue variability and shift some HIV revenue from Quarter 1 into Quarter 2 and from Quarter 2 into Quarter 3.
In diabetes care, the Premier Hb9210 HbA1c laboratory solution earned IFCC Gold Classification for 2026 and obtained multiple regulatory clearances for a next‑generation high‑capacity HbA1c column system. Trinity Biotech is intensifying commercial efforts in the United States, Brazil, and distributor markets, while also consolidating certain haemoglobin manufacturing processes at other group sites to expand capacity and reduce costs.
Trinity Biotech PLC Schedule 13G shows Novus Diagnostics Ltd. reports beneficial ownership of 1,119,988 American Depositary Shares, representing 5.99% of the ADS class based on 18,710,000 ADS outstanding as reported. The filing states Novus has sole voting and dispositive power for these 1,119,988 ADS.
Trinity Biotech plc entered a standby equity purchase agreement allowing up to $25,000,000 of ADS purchases and registers up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The Company delivered 175,537 Commitment ADSs as a fee and paid a $35,000 structuring fee. Under the Purchase Agreement the per-ADS purchase price equals 0.97 times the lowest daily VWAP in a three-Trading-Day period or 0.95 times the VWAP in a one-Trading-Day period. The Investor is subject to a 4.99% beneficial ownership cap; separate Perceptive conversion instruments include a 9.9% cap. The prospectus registers resale by YA II PN, LTD., and Trinity will not receive proceeds from resales; proceeds to Trinity, if any, would result only from ADSs Trinity elects to sell to the Investor under the Purchase Agreement. Shares outstanding figures and other capitalization metrics are reported in the prospectus.
Trinity Biotech plc files a prospectus supplement registering for resale up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs, for sale by selling shareholders.
The supplement also furnishes Form 6-K disclosures: (1) a Nasdaq notice that the company does not meet the MVPHS $15,000,000 requirement and has until August 18, 2026 to regain compliance, and (2) a Standby Equity Purchase Agreement with YA II PN, Ltd. providing an up-to $25,000,000 financing commitment (term to February 24, 2029), an Aggregate Advance Share Cap of 35,107,429 ADSs, and a Commitment Fee of 175,537 ADSs.
Trinity Biotech plc registered for resale up to 35,282,966 ADSs (each ADS = 20 ordinary shares). The ADSs include 175,537 Commitment ADSs delivered as a structuring fee and up to 35,107,429 ADSs issuable under a Standby Equity Purchase Agreement providing for up to $25,000,000 of ADS purchases.
The Purchase Agreement dated February 24, 2026 allows the company, at its option, to sell ADSs to YA II PN, LTD. during a commitment period ending the earlier of February 24, 2029 or purchase of the commitment amount. Pricing is 0.97× VWAP for a three-Trading-Day period or 0.95× VWAP for a one-Trading-Day period. The prospectus states the Selling Securityholder will pay resale expenses and the company will not receive proceeds from resales; the company may receive gross proceeds up to $25 million only from ADSs it elects to sell to the Investor under the Purchase Agreement. Shares outstanding were reported as 374,406,640 ordinary shares as of February 22, 2026. The filing also discloses Nasdaq bid-price and market-value deficiency notices, with cure periods extending into August 2026.